CN106421219A - Ointment for treating chronic eczema and preparation method thereof - Google Patents
Ointment for treating chronic eczema and preparation method thereof Download PDFInfo
- Publication number
- CN106421219A CN106421219A CN201611057742.3A CN201611057742A CN106421219A CN 106421219 A CN106421219 A CN 106421219A CN 201611057742 A CN201611057742 A CN 201611057742A CN 106421219 A CN106421219 A CN 106421219A
- Authority
- CN
- China
- Prior art keywords
- parts
- ointment
- fructus
- herba
- aloe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 46
- 239000002674 ointment Substances 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 210000000582 semen Anatomy 0.000 claims abstract description 21
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 20
- 241001116389 Aloe Species 0.000 claims abstract description 20
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims abstract description 20
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 20
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 20
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 239000012567 medical material Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000000341 volatile oil Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000004821 distillation Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 3
- 238000001256 steam distillation Methods 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 2
- 241000372132 Hydrometridae Species 0.000 claims 1
- 238000007654 immersion Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 16
- 208000024891 symptom Diseases 0.000 abstract description 13
- 208000003251 Pruritus Diseases 0.000 abstract description 10
- 238000001035 drying Methods 0.000 abstract description 4
- 230000007803 itching Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 235000001759 Citrus maxima Nutrition 0.000 abstract 1
- 244000276331 Citrus maxima Species 0.000 abstract 1
- 241000233839 Commelina communis Species 0.000 abstract 1
- 241000244987 Daiswa polyphylla Species 0.000 abstract 1
- 235000003434 Sesamum indicum Nutrition 0.000 abstract 1
- 244000000231 Sesamum indicum Species 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 21
- 208000010668 atopic eczema Diseases 0.000 description 18
- 208000002193 Pain Diseases 0.000 description 13
- 241000700199 Cavia porcellus Species 0.000 description 11
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 240000006409 Acacia auriculiformis Species 0.000 description 5
- 206010011224 Cough Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 4
- 206010012442 Dermatitis contact Diseases 0.000 description 4
- VYZAHLCBVHPDDF-UHFFFAOYSA-N Dinitrochlorobenzene Chemical compound [O-][N+](=O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 VYZAHLCBVHPDDF-UHFFFAOYSA-N 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 208000010247 contact dermatitis Diseases 0.000 description 4
- 230000035618 desquamation Effects 0.000 description 4
- 210000003026 hypopharynx Anatomy 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010017533 Fungal infection Diseases 0.000 description 3
- 206010020741 Hyperpyrexia Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 231100000321 erythema Toxicity 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 201000005404 rubella Diseases 0.000 description 3
- 239000003440 toxic substance Substances 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 2
- 241001655769 Androsace Species 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 201000000297 Erysipelas Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019909 Hernia Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 208000005374 Poisoning Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 208000002399 aphthous stomatitis Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- BCSTWFQGKOAWED-HUCPNFHCSA-N pevisone Chemical compound O[N+]([O-])=O.C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1.C1CC2=CC(=O)C=C[C@]2(C)C2(F)[C@@H]1[C@@H]1C[C@@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O BCSTWFQGKOAWED-HUCPNFHCSA-N 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
- 244000207032 American speedwell Species 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010005913 Body tinea Diseases 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000903946 Clematidis Species 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010947 Coordination abnormal Diseases 0.000 description 1
- 206010012504 Dermatophytosis Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001460074 Microsporum distortum Species 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000081623 Sabia parviflora Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 241000522620 Scorpio Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010043458 Thirst Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 206010067197 Tinea manuum Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241001251949 Xanthium sibiricum Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000002390 adhesive tape Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000002804 anti-anaphylactic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- -1 dinitro-chlorine propiophenone Chemical compound 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960003913 econazole Drugs 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004247 hand Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000016290 incoordination Diseases 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 239000009490 scorpio Substances 0.000 description 1
- 238000006748 scratching Methods 0.000 description 1
- 230000002393 scratching effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000003875 tinea corporis Diseases 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/634—Forsythia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to an ointment for treating chronic eczema and a preparation method thereof. The ointment is prepared from the components in parts by weight: 8 to 14 parts of fructus kochiae, 10 to 25 parts of semen luffae, 20 to 40 parts of radix sophorae flavescentis, 10 to 25 parts of aloe, 8 to 12 parts of pachyrhizua angulatus, 6 to 12 parts of borneol, 4 to 10 parts of herba menthae, 1 to 4 parts of benne oil, 6 to 13 parts of fructus forsythiae, 8 to 17 parts of fructus arctii, 4 to 10 parts of shaddock ped, 4 to 13 parts of paris polyphylla, 8 to 16 parts of cooked radix notoginseng, and 10 to 14 parts of commelina communis. According to the ointment for treating the chronic eczema and the preparation method thereof provided by the invention, an inventor pays attention to Yin-Yang balance, and a prescription is mainly used for clearing heat and drying dampness, and dispelling wind and arresting itching. The ointment has an fast effect on eliminating symptoms of the chronic eczema and relieving clinical symptoms, treats both symptoms and root causes, is low in prognosis recurrence rate, convenient to use without toxic or side effects, convenient to popularize and apply, and simple in preparation process, and can be industrially produced in batch.
Description
Technical field
The present invention relates to Chinese medicine composition, and in particular to a kind of ointment for treating chronic eczema and its preparation side
Method.
Background technology
Eczema is the inflammatory dermatoses of a kind of common epidermis for being caused by multiple internal and external factors and high dermis. which is special
Point is conscious violent prurituss, and skin lesion pleomorphism is symmetrical, has and oozes out tendency, the chronic course of disease, easy recurrent exerbation.Multiple it is born in 5
Child within year, is also found in adult, after infection herpes simplex virus, about through 5-9 days incubation periods, unexpected hyperpyrexia (39-40
DEG C), general malaise, Nausea and vomiting and the poisoning symptom such as drowsiness.Erythra starts from original skins such as face, neck, upper limb and trunk
Sick position, it is also possible to occur on normal skin.Lower limb are rare.Erythra feature：Original erythra increases, and occurs suddenly many intensive
Vesicle, rapidly going to pustule, bleb top has omphalos, base substrate substantially red and swollen.Sometimes erythra fusion slabbing, after 1-2 week
Erythra dries incrustation, leaves pigmentation and superficial scars.Lymphadenectasis nearby.Can concurrently pharyngitis, tonsillitiss, nose
Inflammation, otitis media, conjunctivitis, keratitis or corneal ulcer, pneumonia and encephalitis etc..
Eczema is referred to as eczema of lower limb or dampness skin ulcer in Chinese medicine.So-called poison, refers to some pyretic toxicity, make body produce repel and
Sensitivity response, and these pyretic toxicity are probably to be led to by food, medicine or articles for daily use.Wet to what, refer to physical function by dampness
So that dull.It is moisture content to have seventy percent by what human body, if the operation of water is stagnated having some setbacks, body will locate the wet state of what, and symptom is
Extremity are heavy, edema, incoordination between the spleen and stomach, soft stools etc..Chronic eczema is not often because acute, subacute eczema recurrent exerbation more turns
For chronic eczema；Also can start as chronic eczema.Show as illing skin to thicken, infiltrate, brownish red or pigmentation, surface
Coarse, squama is covered, or is formed a scab because scratching.Conscious acute pruritus.It is common in shank, handss, foot, the fossa cubitalis, nest, pudendum, anus
Etc..The course of disease is indefinite, easily recurs, does not recover for a long time.Preparation currently, with respect to chronic eczema has had a lot, is more common in Western medicine, but
, using Western medicine, there is certain dependency, easily recurrence and or many, or rare hormone composition, and with suitable side effect,
Treatment on market with regard to Chinese medicine also has much, but it is little to reach ideal effect.The medicine for the treatment of eczema is various.Western medicine class
Medicine mainly adopt antianaphylactic treatment, not have effect a radical cure curative effect, Chinese medicine class treat eczema medicine also report for work more.
Chinese patent CN104383087A, discloses a kind of medicine for treating skin eczema, by the material of following weight portion
Make：Sabia parviflora Wall.ex Roxb 500-1000 part, Herba Fici Stenophyliae 700-1200 part, Herba Lycopodii Obscuri 500-1000 part, Herba Clematidis tanguticae 500-800
Part, field Radix Arnebiae (Radix Lithospermi) 600-900 part, Caulis Arcangelisiae 500-800 part, northern Herba Androsaces Umbellatae (Herba Androsaces Coccineae) 600-900 part, field fiber crops 500-1000 part, Herba Chloranthi Henryi (Herba Choranthi seu Lysimachiae)
600-900 part, Herba Saussureae gramineae 500-800 part, purslane speedwell Herba 500-800 part and Herba Rabdosiae Sculponeatae 500-900 part.
Chinese patent CN104306806A, discloses a kind of Chinese medicine composition for treating eczema, by the Chinese medicine of following component
Raw material constitutes：Herba Schizonepetae 15-30 part, Radix Rehmanniae 10-20 part, Flos Chrysanthemi Indici 10-20 part, parching to brown Siberian cocklebur 8-15 part, Scorpio 2-5 part, crow
Bean clothing 10-20 part, Radix Sophorae Flavescentiss 10-20 part, Folium Isatidiss 10-20 part, Herba Verbenae 15-25 part, Semen Coicis 10-20 part, Herba Taraxaci 5-15 part.
But above-mentioned Chinese Herbs are general, it is quite necessary to make great efforts to research and develop the treatment eczema of evident in efficacy, treating both the principal and secondary aspects of a disease
Chinese medicine composition.
Content of the invention
For above technological deficiency, the present invention is in depth studied and creative work through inventor, has obtained one kind
The pharmacy prescription for the treatment of chronic eczema, is especially suitable for chronic eczema, for the discovery that the present inventor is pleasantly surprised, the medicament of the prescription
Effect good, good stability.
Specifically, the concrete scheme of the present invention is realized in：
First, inventor provides a kind of pharmaceutical preparation for treating chronic eczema according to drug matching experience, contains in prescription
Some Chinese medicine ingredients are：The Fructus Kochiae, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Oleum Sesami, Fructus Forsythiae, Fructus Arctii, Pericarpium Citri grandiss,
Rhizoma Paridis, cooked Radix Notoginseng, Herba Commelinae.
Inventor carries out a large amount of investigative tests to the consumption of drug component, and each raw material dosage is in the weight portion model of the present invention
Enclose all and there is preferable curative effect, described formula and component are：Fructus Kochiae 8-14 part, Semen Luffae 10-25 part, Radix Sophorae Flavescentiss 20-40
Part, Aloe 10-25 part, Pachyrhizua angulatus 8-12 part, Borneolum Syntheticum 6-12 part, Herba Menthae 4-10 part, Oleum Sesami 1-4 part, Fructus Forsythiae 6-13 part, Fructus Arctii 8-
17 parts, Pericarpium Citri grandiss 4-10 part, Rhizoma Paridis 4-13 part, cooked Radix Notoginseng 8-16 part, Herba Commelinae 10-14 part.
The formula of above-mentioned weight portion is carried out preferably, reaching superior technique effect, preferred formula is：The Fructus Kochiae 11
Part, 17.5 parts of Semen Luffae, 30 parts of Radix Sophorae Flavescentiss, 17.5 parts of Aloe, 10 parts of Pachyrhizua angulatus, 9 parts of Borneolum Syntheticum, 7 parts of Herba Menthae, 2.5 parts of Oleum Sesami, Fructus Forsythiae
10.5 parts, 12.5 parts of Fructus Arctii, 7 parts of Pericarpium Citri grandiss, 8.5 parts of Rhizoma Paridis, 12 parts of cooked Radix Notoginseng, 12 parts of Herba Commelinae.
The formula of above-mentioned weight portion is carried out preferably, reaching superior technique effect, most preferred formula is：The Fructus Kochiae
12 parts, 18.5 parts of Semen Luffae, 31 parts of Radix Sophorae Flavescentiss, 18.5 parts of Aloe, 11 parts of Pachyrhizua angulatus, 10 parts of Borneolum Syntheticum, 8 parts of Herba Menthae, 3 parts of Oleum Sesami, Fructus Forsythiae
11.5 parts, 13.5 parts of Fructus Arctii, 8 parts of Pericarpium Citri grandiss, 9.5 parts of Rhizoma Paridis, 13 parts of cooked Radix Notoginseng, 13 parts of Herba Commelinae.
The function of each taste Chinese crude drug used in the Chinese medicine preparation of the treatment eczema of the present invention is as follows：
Cooked Radix Notoginseng：Sweet in the mouth, warm in nature.
Return through：Return liver, stomach.
Indication：Dissipate stasis of blood hemostasis, subduing swelling and relieving pain.For spitting blood, spit blood, epistaxis, have blood in stool, metrorrhagia, traumatic hemorrhage, chest and abdomen
Twinge, tumbling and swelling.
Pericarpium Citri grandiss：Acrid in the mouth, warm in nature
Return through：Spleen；Kidney；Bladder warp.
Indication：Alleviating distention in middle-JIAO qi-regulating；Help digestion；Resolving sputum；Relieving cough and asthma.The main stagnation of QI is uncomfortable in chest；Coldness and pain in the epigastrium；Food stagnation；Dysentery；Cough
Breathe heavily；Hernia.
Return through：Return kidney, bladder warp.
Indication：Clearing away heat-damp and promoting diuresis, dispelling wind for relieving itching, for difficulty and pain in micturition, pudendal pruritus leukorrhagia, rubella, eczema, skin pruritus.
Semen Luffae：Taste bitter in the mouth；Cold in nature
Indication：Heat clearing away；Diuretic；Relieving constipation；Anthelmintic.
Aloe：Bitter in the mouth, cold in nature.
Return through：Return liver, stomach, large intestine channel.
Indication：Removing heat from the liver, relieving constipation, for constipation, infantile malnutrition, infantile convulsion external treatment exudative dermatitis.
Radix Sophorae Flavescentiss：Bitter in the mouth, cold in nature.
Return through：GUIXIN, liver, stomach, large intestine, bladder warp.
Indication：Heat clearing and damp drying, parasite killing diuresis, have blood in stool for hematodiarrhoea, jaundice urine retention, leucorrhea with red and white discharge.
Pachyrhizua angulatus
Borneolum Syntheticum：Bitter in the mouth, cold in nature.
Return through：GUIXIN, spleen, lung meridian.
Indication：Inducing resuscitation of having one's ideas straightened out, clearing away heat to alleviate pain.Faint for calentura coma, convulsion, apoplexy syncope due to accumulation of phlegm, bstruction of the circulation of vital energy is fainted cruelly, attacked by pestiferous factors dusk
Fan, conjunctival congestion, aphtha, laryngopharynx swelling and pain, auditory meatus are suppurated.
Herba Menthae：Taste is sweet, cool in nature.
Return through：Return lung, Liver Channel, dispelling wind-heat, refresh oneself, rash, for anemopyretic cold, pathogenic wind-warm from the beginning of, headache, conjunctival congestion,
Sore throat, aphtha, rubella, measles, Breast bilges frowsty about.
Fructus Forsythiae：Bitter in the mouth, is slightly cold.
Return through：Return lung, the heart, small intestine meridian.
Indication：Heat-clearing and toxic substances removing, dispersing swelling and dissipating binds.For carbuncle, scrofula, acute mastitis, erysipelas, anemopyretic cold, epidemic febrile disease from the beginning of,
Warm is joined the army, hyperpyrexia excessive thirst, and coma sends out speckle, pyretic stranguria urine retention.
Fructus Arctii：Acrid in the mouth, cold in nature.
Return through：Attach to the lung and stomach meridians.
Indication：Dispelling wind and heat pathogens, lung qi dispersing rash, resolving toxin and disinhibiting the throat.For anemopyretic cold, cough with copious phlegm, measles, rubella,
Laryngopharynx swelling and pain, mumps erysipelas, carbuncle sore tumefacting virus.
Pericarpium Citri grandiss：Acrid in the mouth, warm in nature
Return through：Spleen；Kidney；Bladder warp.
Indication：Alleviating distention in middle-JIAO qi-regulating；Help digestion；Resolving sputum；Relieving cough and asthma.The main stagnation of QI is uncomfortable in chest；Coldness and pain in the epigastrium；Food stagnation；Dysentery；Cough
Breathe heavily；Hernia.
Rhizoma Paridis：Bitter in the mouth, is slightly cold；Slightly poisonous.
Return through：Return liver warp.
Indication：Heat-clearing and toxic substances removing, reducing swelling and alleviating pain, cool liver is calmed the frightened.For furuncle carbuncle, laryngopharynx swelling and pain, venom, fall
Flutter the pain of injury, convulsion with spasms.
Herba Commelinae：Sweet in the mouth, cold in nature.
Return through：Return lung, stomach, small intestine meridian.
Indication：Heat-clearing and toxic substances removing, inducing diuresis to remove edema.For anemopyretic cold, hyperpyrexia, laryngopharynx swelling and pain, edema oliguria, heat
Drench puckery pain, carbuncle furunculosis.
In pharmaceutical preparation described above, the Chinese medicine for being used all uses its conventional medicinal part to be used as medicine, in being used
Pharmaceutical quantities are reasonable, have preferable effect for treatment acute eczema after all medicines share.
The pharmaceutical preparation for the treatment of acute eczema of the present invention, external preparation is made in wherein described pharmaceutical preparation,
Described external preparation can be the clinically available exterior-applied formulation, preferably ointment such as water decoction, ointment, gel.
According to the difference of patient, present invention also offers a kind of preparation method of the ointment for treating chronic eczema, the party
Method comprises the steps：
(1) take the Fructus Kochiae, cooked Radix Notoginseng, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Oleum Sesami, Fructus Forsythiae, Fructus Arctii,
Pericarpium Citri grandiss, Rhizoma Paridis and Herba Commelinae are standby；
(2) take Fructus Forsythiae and volatile oil is extracted, volatile oil is collected, the another device storage of the aqueous solution after distillation；
(3) by the Fructus Kochiae, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Fructus Arctii, Pericarpium Citri grandiss, Rhizoma Paridis and Herba Commelinae
11 taste medical materials are added water to cook, and decoction liquor is filtered, and obtains extracting solution；
(4) extracting solution is merged with the aqueous solution after distillation, is concentrated to give clear paste, is dry, and adds cooked Radix Notoginseng, Oleum Sesami to obtain final product emulsifiable paste
Agent.
In above-mentioned preparation method, in step (2), Fructus Forsythiae adopts steam distillation, and amount of water is medical material amount 8-12 times, to soak
0.5-2 hour；In step (3), decocting is boiled 2-4 time, each 0.5-2 hour, and amount of water is medical material 8-12 times amount.
In the above-mentioned composition of the present invention be all according to weight portion as proportioning, can increase according to corresponding proportion aborning or
Reduce, such as large-scale production can by kilogram or ton in units of, small-scale production can be counted in units of mg.Weight can increase
Or reduce, but the raw medicinal herbs weight proportion ratio between each composition can not change.The above part by weight of the present invention be through section
Filter out, and can accordingly increase or decrease the corresponding ratio of adjustment for especial patient such as serious symptom or mild, but increase and decrease
Or reduce less than 300%, effect is constant.
Compared with prior art, inventor focuses on negative and positive coordination in the present invention, and prescription with heat clearing and damp drying, dispelling wind for relieving itching is
Main.Fast, the treating both the principal and secondary aspects of a disease of effect is taken to eliminating the symptom of chronic eczema, alleviating clinical symptoms, recurrence rate after healing is low, and user
Just, have no toxic side effect, easy to utilize.
Specific embodiment
It is obvious to a person skilled in the art that the invention is not restricted to the details of exemplary embodiment of the present invention, Er Qie
In the case of spirit or essential attributes without departing substantially from the present invention, the present invention can be realized in other specific forms.Therefore, no matter
From the point of view of which point, embodiment all should be regarded as exemplary, and be nonrestrictive, the scope of the present invention is by appended power
Profit is required rather than described above is limited, it is intended that all in the implication and scope of the equivalency of claim by falling
Change is included in the present invention.
Embodiment 1：A kind of ointment for treating chronic eczema, containing following weight portion material：
8 grams of the Fructus Kochiae, 10 grams of Semen Luffae, 20 grams of Radix Sophorae Flavescentiss, 10 grams of Aloe, 8 grams of Pachyrhizua angulatus, 6 grams of Borneolum Syntheticum, 4 grams of Herba Menthae, Oleum Sesami 1
Gram, 6 grams of Fructus Forsythiae, 8 grams of Fructus Arctii, 4 grams of Pericarpium Citri grandiss, 4 grams of Rhizoma Paridis, 8 grams of cooked Radix Notoginseng, 10 grams of Herba Commelinae.
Preparation method is：
(1) take the Fructus Kochiae, cooked Radix Notoginseng, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Oleum Sesami, Fructus Forsythiae, Fructus Arctii,
Pericarpium Citri grandiss, Rhizoma Paridis and Herba Commelinae are standby；
(2) take Fructus Forsythiae and volatile oil extracted, volatile oil is collected, using steam distillation, amount of water is medical material amount 8-12 times,
Soak 0.5-2 hour；
(3) by the Fructus Kochiae, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Fructus Arctii, Pericarpium Citri grandiss, Rhizoma Paridis and Herba Commelinae
11 taste medical materials are added water to cook, and decocting is boiled 2-4 time, each 0.5-2 hour, and amount of water is that medical material 8-12 times amount, decoction liquor is filtered, and obtains
Extracting solution；
(4) extracting solution is merged with the aqueous solution after distillation, is concentrated to give clear paste, is dry, and adds cooked Radix Notoginseng, Oleum Sesami to obtain final product Chinese medicine
Compositionss.
Embodiment 2：A kind of ointment for treating chronic eczema, containing following weight portion material：
14 grams of the Fructus Kochiae, 25 grams of Semen Luffae, 40 grams of Radix Sophorae Flavescentiss, 25 grams of Aloe, 12 grams of Pachyrhizua angulatus, 12 grams of Borneolum Syntheticum, 10 grams of Herba Menthae, fiber crops
4 grams of oil, 13 grams of Fructus Forsythiae, 17 grams of Fructus Arctii, 10 grams of Pericarpium Citri grandiss, 13 grams of Rhizoma Paridis, 16 grams of cooked Radix Notoginseng, 14 grams of Herba Commelinae.
Preparation method is with embodiment 1.
Embodiment 3：A kind of ointment for treating chronic eczema, containing following weight portion material：
11 grams of the Fructus Kochiae, 17.5 grams of Semen Luffae, 30 grams of Radix Sophorae Flavescentiss, 17.5 grams of Aloe, 10 grams of Pachyrhizua angulatus, 9 grams of Borneolum Syntheticum, 7 grams of Herba Menthae,
2.5 grams of Oleum Sesami, 10.5 grams of Fructus Forsythiae, 12.5 grams of Fructus Arctii, 7 grams of Pericarpium Citri grandiss, 8.5 grams of Rhizoma Paridis, 12 grams of cooked Radix Notoginseng, 12 grams of Herba Commelinae.
Preparation method is with embodiment 1.
Embodiment 4：A kind of ointment for treating chronic eczema, containing following weight portion material：
12 grams of the Fructus Kochiae, 18.5 grams of Semen Luffae, 31 grams of Radix Sophorae Flavescentiss, 18.5 grams of Aloe, 11 grams of Pachyrhizua angulatus, 10 grams of Borneolum Syntheticum, Herba Menthae 8
Gram, 3 grams of Oleum Sesami, 11.5 grams of Fructus Forsythiae, 13.5 grams of Fructus Arctii, 8 grams of Pericarpium Citri grandiss, 9.5 grams of Rhizoma Paridis, 13 grams of cooked Radix Notoginseng, 13 grams of Herba Commelinae.
Preparation method is with embodiment 1.
Embodiment 5：Animal model test
Pevisone (triamcinolone acetonide econazole cream), indication be 1. with fungal infection or have fungal infection be inclined to skin
Scorching, eczema；2. by dermatophytosises, yeast and mycetogenic inflammatory skin mycosises, such as tinea manus and pedis, tinea corporis, tinea cruris, flower
Speckle tinea；3. diaper dermatitis；4. bridou；5. paronychia；6. the skin mixed infection caused by funguses, antibacterial,
Especially just there is good therapeutic effect to chronic eczema, therefore the present invention is selected and tested as positive control.
5.1st, modeling and packet administration
Cavia porcelluss, pure white undercoat, 250 ± 20g of original body mass, sets up 50 Cavia porcelluss contact eczema models.Per only Cavia porcelluss neck
Back cropping 2cm × 2cm size, 5% dinitro-chlorine propiophenone (DNCB) solution, 25 μ l applies outward sensitization.After 2 weeks, right per only Cavia porcelluss
In ear side applies 100 μ l of 0.1%DNCB solution as exciting, 1 times a week, continuous 4 times.After 3rd time excites, auris dextra skin slightly increases
Thickness, a little desquamation；The 4th excites rear auris dextra skin substantially to thicken, close with the clinical manifestation of human chronic's eczema, and tissue is lived
Inspection shows that (epidermis is thickened, single around dermal vascular for epidermis is slight hyperkeratosiss, focal parakeratosis for the change of chronic eczema
Nucleuss infiltrate), the 4th excites rear 72h, by 50 Cavia porcelluss be randomly divided into Chinese medicine A group (ointment of the embodiment of the present invention 1),
Chinese medicine B group (ointment of the embodiment of the present invention 3), Chinese medicine C group (ointment of the embodiment of the present invention 4), model group (physiology salt
Water) and positive controls, per organizing 10, external is daily 2 times respectively, continuous 10 days.Separately take 10 to be left intact, same
Raise under environment.
5.2nd, testing index
It is discontinued test and appraisal in latter 1 day：
(1) ear swelling degree is surveyed：Determined per only two ear interior thickness of Cavia porcelluss with outside micrometer mono blind method, calculate its difference；
(2) Langerhans (Langerhans) cell counting：Cavia porcelluss auris dextra normal saline is wiped net left drug, is cut
Organize in the middle part of 0.5cm × 0.5cm ear, hair is removed, skin graft of tabulating, mono blind method calculates 10 high power field (HPF) Lang Ge respectively
This cell number of the Chinese, takes its meansigma methods；
(3) corium inflammatory cell is counted：Take fritter auris dextra to organize, specimens paraffin embedding slices, hematoxylin-eosin (HE) is dyeed,
Count 10 high power field (HPF) corium number of inflammatory cells respectively, take its meansigma methods
5.3rd, result
Impact of the different pharmaceutical external to DNCB induction Cavia porcelluss contact eczema model the results are shown in Table 1.
1 different pharmaceutical external of table induces the impact of Cavia porcelluss contact eczema model to DNCB
Note：
Compare with model group, #p<0.05, ##p<0.01；
With positive controls,&p<0.05.
It can be seen from Table 1 that, compared with normal group, model group Cavia porcelluss auris dextra obvious tumefaction, wolf Ge Hansi cell number, true
Skin infiltrating cells number, with significant difference, illustrates that Cavia porcelluss model successfully.Positive controls, Chinese medicine each group contact eczema has
Improve, and with significant difference, and obvious, the therapeutic effect of Chinese medicine B group is better than positive controls and Chinese medicine A
Group and Chinese medicine C group.With the research further to Chinese medicine, effective infection antianaphylaxis components are analyzed, is configured to various externals
Pharmaceutically dosage form, for treating chronic dermatosis, prospect will be very wide.
Embodiment 6：Toxicology test
6.1st, physical data
Big ear white race rabbit, 16, female, body weight 2.1-2.3kg；The ointment of embodiment 1-4.
6.2nd, test method：
From skin, intact healthy family exempts from 16, per organizing 4, is divided into A, B, C, D group, respectively using embodiment 5-8
Its back spinal column both sides is cut by ointment in test for first 24 hours by hair, removes the left and right each about 3cm × 3cm of gross area.Test
When take tested material 0.2ml and be applied on two layers of gauze of 2.5cm × 2.5cm, apply
Side skin of unhairing surface is affixed on, oilpaper is covered, immobilization with adhesive tape.Opposite side skin is used as blank.Close 4 little
Shi Hou, dismantles, and cleans residual tested material with warm water, and the observations in 1,24 and 48 hours after tested material is removed are smeared
Area skin reacts,
6.3rd, experimental result
There is not any erythema in laboratory animal skin, red and swollen, inflammation phenomenon.
According to《Disinfection technology standard》(2012) in, skin wound repair standards of grading judge, ointment of the present invention is to animal
Skin irritation intensity belongs to nonirritant.
Embodiment 7：
7.1st, physical data
Kunming mouse, 40, female, male half and half, body weight 18-22 gram；The ointment of embodiment 1-4.
7.2nd, test method：
Select healthy adult mice 40, body weight 18-22 gram, female, male half and half, per group 10, it is divided into A, B, C, D group, respectively
Using the water decoction of embodiment 1-4, dose design female is that 10ml/kg, oral gavage gives tested material.Animal fasting before gavage
12 hours, free water.Normal diet being given after gavage, is observed two weeks, records poisoning symptom and death condition.
7.3rd, result of the test：
Within 14 day observation period, animal subject is as good as paradoxical reaction, no dead, postmortem no abnormality seen.According to《Disinfection technology
Specification》(2012) in, acute toxicity grading criteria judges, water decoction of the present invention belongs to nontoxic level.
Embodiment 8：The clinical observation of the Chinese medicine preparation eczema of the embodiment of the present invention.
8.1st, physical data
The patient medical because suffering from chronic eczema during accepting in December, 2012 in December, 2015 for medical treatment, 273, male 140,
Age 1-5 year, 3.5 years old mean age；Women 143, age 1-5 year, 3.4 years old mean age.2 groups are randomly divided into, respectively
Treatment group, matched group, between two groups, there was no significant difference for the factor such as the state of an illness, age, with comparability.
8.2nd, therapeutic scheme
Patient in the clinical trial is divided into 2 groups, respectively treatment group and matched group, and wherein packet is the disease according to patient
Feelings and wish, with 7 days as a course for the treatment of.
Treatment group：136, men and women half and half, and affected part wash clean smears the ointment of the appropriate embodiment of the present invention 3, one day
Twice.
Observation group's (Pevisone)：137, man 72, female 75, use to specifications, twice a day.
8.3rd, efficacy assessment standard
Recovery from illness：Eczema erythema disappears, and affected skin switchs to normally, dark red decoloration.
Effectively：Eczema erythema is significantly reduced, and attack times are reduced, and prurituss mitigate, and affected skin does not spread or diffusion velocity
Slow down.
Invalid：Symptom does not disappear or increases.
Bounce-back：Cure latter 3 months and run into hygrothermal environment and still show effect.
Effective percentage：(recovery from illness+take a turn for the better)/patient populations.
Rebound rate：(recovery from illness+take a turn for the better) recurrence/(recovery from illness+take a turn for the better)
8.4th, diagnostic criteria
Diagnostic criteria reference distinguishes chief editor's by Zhao《Clinical dermatology》The clinical criteria of proposition is formulated：Skin multiform
Property：Illing skin infiltration, plump, pigmentation, dry tack free, raw sugar, have a little squama or in lichenization, scratch, incrustation or
Chap, periphery can be dispersed in redness or kermesinus mound pain, speckle mound epidemic disease；It is confined at one or many places more skin, is apt to occur in extremity
The position such as side in the wrong, brothers and pudendum, crissum, how symmetrically property distribution；The chronic course of disease, recurrent exerbation.During acute attack, it is seen that bright
Aobvious sepage.
8.5th, experimental design
Using random, parallel control clinical trial design, receive the corresponding treatment of 20 days.Patient before the treatment and controls respectively
By same index evaluation person, the clinical symptoms of patient are estimated with sign after treating the 20th day, and record in detail.Treatment knot
Shu Hou carries out call-on back by phone to patient's bounce-back situation in 3 months.
8.6th, disease overall therapeutic result
2 treatment group of table and the situation for the treatment of of control group and recurrence afterwards in 3 months
| Group | Recovery from illness | Effectively | Invalid | Total effective rate | Bounce-back | Rebound rate |
| Treatment group | 98 | 37 | 1 | 99.26% | 2 | 2.04% |
| Matched group | 55 | 66 | 26 | 81.02 | 17 | 30.9% |
From table 2 it can be seen that through the treatment of 20 days, treatment group is compared with observation group total effective rate, is united with significant
Difference (P learned by meter<0.01), the effective percentage for the treatment of group is more than 99%, and the effective percentage of matched group is more than 80%；Treatment group and sight
Examine group rebound rate to compare, with significant significant difference (P<0.01), the rebound rate of matched group high nearly 30.9%, thus
It can be seen that western medicine has obvious dependency, therapeutic effect is significantly lower than treatment group.
8.7th, classical case
Case 1：Hao, man, 31 years old, Sichuan people from Chengdu, in June, 2013 finds that between palm, finger, water persistently occurs in face
Bubble, and constantly desquamation, using Western medicine ointment invalid after, itch sometimes, come upon somebody's introduction to go to a doctor at the court, using embodiment
After the Chinese medicine of the medicinal external emulsifiable paste agent treatment eczema described in 3 coats a course for the treatment of, affected part starts to dry, desquamation has and substantially changes
Kind, to adhere to employing 1 course for the treatment of, symptom is wholly absent, and call-on back by phone does not recur within 3 months.
Case 2：Certain is spent, man 5 years old, Shandong people from Linshu, in January, 2014 carrys out our hospital's treatment, and patient main suit's patient's thoracic dorsal plays water
Bubble is more than 1 year, and many pimples, prurituss flowing water, suppurates, after drying and constantly desquamation, and through taking vitamin, external application boric acid wet cloth is equal
Carrying out our hospital's inspection at the beginning of not obtaining effect, 2015, affected part is washed with 4 water decoction of the embodiment of the present invention, after 2 courses for the treatment of, symptom disappears completely
Lose, call-on back by phone does not recur within 3 months.
Claims (8)
1. a kind of ointment for treating chronic eczema, it is characterised in that described ointment includes following Chinese crude drug：The Fructus Kochiae,
Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Oleum Sesami, Fructus Forsythiae, Fructus Arctii, Pericarpium Citri grandiss, Rhizoma Paridis, cooked Radix Notoginseng, Herba Commelinae.
2. ointment according to claim 1, it is characterised in that described ointment includes following weight portion Chinese crude drug：
Fructus Kochiae 8-14 part, Semen Luffae 10-25 part, Radix Sophorae Flavescentiss 20-40 part, Aloe 10-25 part, Pachyrhizua angulatus 8-12 part, Borneolum Syntheticum 6-12 part, Herba Menthae
4-10 part, Oleum Sesami 1-4 part, Fructus Forsythiae 6-13 part, Fructus Arctii 8-17 part, Pericarpium Citri grandiss 4-10 part, Rhizoma Paridis 4-13 part, cooked Radix Notoginseng 8-16 part,
Herba Commelinae 10-14 part.
3. ointment according to claim 1, it is characterised in that described ointment includes following weight portion Chinese crude drug：
11 parts of the Fructus Kochiae, 17.5 parts of Semen Luffae, 30 parts of Radix Sophorae Flavescentiss, 17.5 parts of Aloe, 10 parts of Pachyrhizua angulatus, 9 parts of Borneolum Syntheticum, 7 parts of Herba Menthae, Oleum Sesami 2.5
Part, 10.5 parts of Fructus Forsythiae, 12.5 parts of Fructus Arctii, 7 parts of Pericarpium Citri grandiss, 8.5 parts of Rhizoma Paridis, 12 parts of cooked Radix Notoginseng, 12 parts of Herba Commelinae.
4. ointment according to claim 1, it is characterised in that described ointment includes following weight portion Chinese crude drug：
12 parts of the Fructus Kochiae, 18.5 parts of Semen Luffae, 31 parts of Radix Sophorae Flavescentiss, 18.5 parts of Aloe, 11 parts of Pachyrhizua angulatus, 10 parts of Borneolum Syntheticum, 8 parts of Herba Menthae, Oleum Sesami 3
Part, 11.5 parts of Fructus Forsythiae, 13.5 parts of Fructus Arctii, 8 parts of Pericarpium Citri grandiss, 9.5 parts of Rhizoma Paridis, 13 parts of cooked Radix Notoginseng, 13 parts of Herba Commelinae.
5. a kind of ointment for preparing described in claim 1-4, it is characterised in that specific preparation process is：
(1) take the Fructus Kochiae, cooked Radix Notoginseng, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Oleum Sesami, Fructus Forsythiae, Fructus Arctii, Pericarpium Citri grandiss,
Rhizoma Paridis and Herba Commelinae are standby；
(2) take Fructus Forsythiae and volatile oil is extracted, volatile oil is collected, the another device storage of the aqueous solution after distillation；
(3) by the Fructus Kochiae, Semen Luffae, Radix Sophorae Flavescentiss, Aloe, Pachyrhizua angulatus, Borneolum Syntheticum, Herba Menthae, Fructus Arctii, Pericarpium Citri grandiss, Rhizoma Paridis and 11 taste of Herba Commelinae
Medical material is added water to cook, and decoction liquor is filtered, and obtains extracting solution；
(4) extracting solution is merged with the aqueous solution after distillation, is concentrated to give clear paste, is dry, and is added cooked Radix Notoginseng, Oleum Sesami, is obtained final product.
6. ointment according to claim 5, it is characterised in that：In step (2), Fructus Forsythiae adopts steam distillation, adds water
Measure as medical material amount 8-12 times, immersion 0.5-2 hour；In step (3), decocting is boiled 2-4 time, each 0.5-2 hour, and amount of water is medicine
Material 8-12 times amount.
7. ointment according to claim 1, it is characterised in that：Described ointment is preparing treatment chronic eczema medicine
In purposes.
8. ointment according to claim 1, it is characterised in that：Described ointment is preparing treatment children's chronic eczema
Purposes in medicine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016102619265 | 2016-04-24 | ||
| CN201610261926.5A CN105853680A (en) | 2016-04-24 | 2016-04-24 | Cream for treating chronic eczema and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106421219A true CN106421219A (en) | 2017-02-22 |
Family
ID=56628918
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610261926.5A Pending CN105853680A (en) | 2016-04-24 | 2016-04-24 | Cream for treating chronic eczema and preparation method thereof |
| CN201611057742.3A Withdrawn CN106421219A (en) | 2016-04-24 | 2016-11-27 | Ointment for treating chronic eczema and preparation method thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610261926.5A Pending CN105853680A (en) | 2016-04-24 | 2016-04-24 | Cream for treating chronic eczema and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105853680A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262188A (en) * | 2021-06-23 | 2021-08-17 | 上海林清轩生物科技有限公司 | Plant extract for relieving eczema and preparation method and application thereof |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106266876A (en) * | 2016-09-27 | 2017-01-04 | 泰山医学院 | A kind of for compound ointment treating eczema and preparation method thereof |
| CN106177693A (en) * | 2016-09-27 | 2016-12-07 | 泰山医学院 | A kind of Chinese medicine for treating eczema and compound recipe solution thereof |
| CN106310063A (en) * | 2016-09-27 | 2017-01-11 | 泰山医学院 | Compound gel for treating eczema and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785836A (en) * | 2009-01-23 | 2010-07-28 | 冷少华 | Traditional Chinese medicine ointment, preparation method and application thereof for skin disease treatment |
-
2016
- 2016-04-24 CN CN201610261926.5A patent/CN105853680A/en active Pending
- 2016-11-27 CN CN201611057742.3A patent/CN106421219A/en not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785836A (en) * | 2009-01-23 | 2010-07-28 | 冷少华 | Traditional Chinese medicine ointment, preparation method and application thereof for skin disease treatment |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113262188A (en) * | 2021-06-23 | 2021-08-17 | 上海林清轩生物科技有限公司 | Plant extract for relieving eczema and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105853680A (en) | 2016-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1325083C (en) | Medicinal composition for removing dampness to relieve itching and its preparation method and uses | |
| CN103041173B (en) | Traditional Chinese medicine external preparation for curing dermatitis and eczema and preparing method thereof | |
| CN101979041B (en) | Chinese medicinal preparation for treating various dermatoses | |
| CN104474076A (en) | Traditional Chinese medicine composition for treating eczema | |
| CN102178804B (en) | Chinese medicinal composition for treating perianal eczema and preparation method thereof | |
| CN101869626B (en) | Chinese medicinal compound preparation private care liquid, and preparation and application thereof | |
| CN106421219A (en) | Ointment for treating chronic eczema and preparation method thereof | |
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN102178877B (en) | External preparation for treating eczema of scrotum and preparation method thereof | |
| CN101601782B (en) | Compound tincture for treating dermatophytosis | |
| CN101214341B (en) | Medicine preparation for curing psoriasis and preparation thereof | |
| CN102847020B (en) | Preparation method of traditional Chinese medicine wet tissue for clearing heat, detoxifying, promoting diuresis and relieving itching | |
| CN104958633A (en) | Medicine for treating acne vulgaris and preparation method thereof | |
| CN104491629A (en) | External traditional Chinese medicinal composition for treating perianal eczema, and preparation method thereof | |
| CN104706953A (en) | Traditional Chinese medicine preparation for treating chronic cervicitis | |
| CN104784346A (en) | Pruritus treating traditional Chinese medicine lotion preparation method | |
| CN103432485A (en) | Chinese medicinal preparation for treating urinary calculus and preparation method | |
| CN103191399A (en) | Traditional Chinese medicine composition for treating bronchial asthma in acute-outbreak period | |
| CN103041194B (en) | Traditional Chinese medicine composition for curing chronic eczema and preparation method thereof | |
| CN104189190A (en) | Traditional Chinese medicine medicated bath for treating pruritic tinea manuum and preparing method thereof | |
| CN102861273A (en) | Preparation method of traditional Chinese medicine wet wipes for treating exudative children eczema | |
| CN103041161A (en) | Traditional Chinese medicine composition for oral administration for curing acute eczema and preparation method thereof | |
| CN103479915B (en) | Traditional Chinese medicine composition for treating acute nephritis and preparation method thereof | |
| CN103028045A (en) | Externally applied traditional Chinese medicine composition for treating acute eczema and preparation method of traditional Chinese medicine composition | |
| CN106421087A (en) | Pharmaceutical preparation for treating acute eczema, and use of pharmaceutical preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170222 |
|
| WW01 | Invention patent application withdrawn after publication |